Literature DB >> 23702087

Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.

Shuichiro Kobayashi1, Yasuhisa Fujii2, Fumitaka Koga1, Minato Yokoyama1, Junichiro Ishioka1, Yoh Matsuoka1, Noboru Numao1, Kazutaka Saito1, Hitoshi Masuda1, Kazunori Kihara1.   

Abstract

PURPOSE: Our previous retrospective study reported that bladder neck involvement (BNI), as well as tumor grade and stage, was a significant risk factor for progression in primary non-muscle invasive bladder cancer (NMIBC). We prospectively validated BNI as a significant predictor for progression using a new cohort of patients with primary NMIBC. PATIENTS AND METHODS: A total of 297 new Japanese patients who underwent transurethral resection and were pathologically diagnosed with Ta or T1 urothelial carcinoma were enrolled in this prospective study. Clinicopathologic data were collected at study entry. Multivariate Cox proportional hazards regression models were performed to identify the independent predictors for progression. A predictive scoring model for progression was developed using the regression coefficients (RCs) from the final multivariate model. The predictive ability of the model was assessed using Harrell's c-index.
RESULTS: With a median follow-up of 37 months, 16 patients (5.4%) progressed. Progression probability at 1 and 5 years were 1.5% and 8.0%, respectively. Multivariate analysis revealed that histologic grade 3 (hazard ratio [HR] 9.45, P = 0.0004, RC 2.25), pathologic T1 stage (HR 6.91, P = 0.0014, RC 1.93), and BNI (HR 11.75, P = 0.0009, RC 2.46) were all independent predictors of progression. When all 3 variables were scored as 1 point and the patients were divided into 3 groups, progression rates were clearly discriminated (P<0.0001). The c-index was 0.80.
CONCLUSIONS: This prospective validation study has shown that BNI is a significant prognostic factor for progression in primary NMIBC. The scoring model including BNI enables the physician to classify patients with primary NMIBC into 3 groups with clearly different progression rates.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder neck; Carcinoma; Progression; Urinary bladder; Urinary bladder neoplasms

Mesh:

Year:  2013        PMID: 23702087     DOI: 10.1016/j.urolonc.2013.04.001

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  5 in total

1.  Low-Grade, Multiple, Ta Non-muscle-Invasive Bladder Tumors: Tumor Recurrence and Worsening Progression.

Authors:  R B Nerli; Shridhar C Ghagane; K Shankar; Adarsh C Sanikop; Murigendra B Hiremath; Neeraj S Dixit; Laxman Magadum
Journal:  Indian J Surg Oncol       Date:  2018-01-29

2.  Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progression.

Authors:  Shugo Yajima; Soichiro Yoshida; Taro Takahara; Yuki Arita; Hiroshi Tanaka; Yuma Waseda; Minato Yokoyama; Junichiro Ishioka; Yoh Matsuoka; Kazutaka Saito; Kazunori Kihara; Yasuhisa Fujii
Journal:  Eur Radiol       Date:  2019-03-19       Impact factor: 5.315

3.  Evaluation of Vesical Imaging-Reporting and Data System (VI-RADS) scoring system in predicting muscle invasion of bladder cancer.

Authors:  Shenghua Liu; Feijia Xu; Tianyuan Xu; Yang Yan; Xudong Yao; Guangyu Tang
Journal:  Transl Androl Urol       Date:  2020-04

4.  The dog as an animal model for bladder and urethral urothelial carcinoma: Comparative epidemiology and histology.

Authors:  Simone de Brot; Brian D Robinson; Tim Scase; Llorenç Grau-Roma; Eleanor Wilkinson; Stephen A Boorjian; David Gardner; Nigel P Mongan
Journal:  Oncol Lett       Date:  2018-05-30       Impact factor: 2.967

5.  Prognostic significance of bladder neck involvement in non-muscle-invasive bladder cancer: A SEER database analysis with 19,919 patients.

Authors:  Xiangpeng Zhan; Ju Guo; Luyao Chen; Wen Deng; Xiaoqiang Liu; Ke Zhu; Weipeng Liu; Bin Fu
Journal:  Cancer Med       Date:  2021-08-23       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.